SCHEMBL19018136

SCHEMBL19018136

c1ccc(Nc2ccc(NCCNc3ccc(Nc4ccccc4)cc3)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.68
HSD17B10 Q99714 6/20 0.68
L3MBTL1 Q9Y468 4/20 0.68
ALOX12 P18054 4/20 0.68
TSHR P16473 4/20 0.68
TDP1 Q9NUW8 3/20 0.68
ALOX15 P16050 3/20 0.68
MAPK1 P28482 2/20 0.68
PTGS1 P23219 1/20 0.68
SLC6A2 P23975 1/20 0.68
PTGS2 P35354 1/20 0.68
HTR2B P41595 1/20 0.68
MAPT P10636 6/20 0.64
CYP3A4 P08684 5/20 0.54
HPGD P15428 2/20 0.54
HTT P42858 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
MEN1 O00255 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7149348 0.90 ALDH1A1 (0.73) ALDH1A1HSD17B10L3MBTL1ALOX12TSHR
SCHEMBL232188 0.89 MAPT (0.78) ALDH1A1HSD17B10L3MBTL1ALOX12TSHR
SCHEMBL18660177 0.88 ALDH1A1 (0.70) ALDH1A1HSD17B10L3MBTL1ALOX12TSHR
SCHEMBL18660198 0.88 ALDH1A1 (0.70) ALDH1A1HSD17B10L3MBTL1ALOX12TSHR
SCHEMBL18660199 0.88 ALDH1A1 (0.70) ALDH1A1HSD17B10L3MBTL1ALOX12TSHR
SCHEMBL19018359 0.88 ALDH1A1 (0.70) ALDH1A1HSD17B10L3MBTL1ALOX12TSHR
SCHEMBL809568 0.86 ALDH1A1 (0.56) ALDH1A1HSD17B10L3MBTL1ALOX12TSHR
SCHEMBL11655423 0.86 RECQL (0.61) ALDH1A1HSD17B10L3MBTL1ALOX12TSHR
SCHEMBL6416019 0.86 MAPT (0.74) ALDH1A1HSD17B10L3MBTL1ALOX12TSHR
SCHEMBL1562142 0.86 MAPT (0.74) ALDH1A1HSD17B10L3MBTL1ALOX12TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3634939-B1 METHODS OF MAKING COMPOUNDS HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY EASTMAN CHEM CO (US) 2021-03-24 EP disclosed
EP-3792245-A1 COMPOUNDS WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SAID COMPOUNDS Eastman Chemical Company (US) 2021-03-17 EP disclosed
EP-3394028-B1 COMPOUNDS WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SAID COMPOUNDS EASTMAN CHEM CO (US) 2020-11-04 EP disclosed
US-10611719-B2 Methods of making compounds and mixtures having antidegradant and antifatigue efficacy EASTMAN CHEMICAL COMPANY (US) 2020-04-07 US disclosed
US-10611719-B2 Methods of making compounds and mixtures having antidegradant and antifatigue efficacy EASTMAN CHEMICAL COMPANY (US) 2020-04-07 US disclosed
US-10428009-B2 Methods of making compounds and mixtures having antidegradant and antifatigue efficacy EASTMAN CHEMICAL COMPANY (US) 2019-10-01 US disclosed
US-10428009-B2 Methods of making compounds and mixtures having antidegradant and antifatigue efficacy EASTMAN CHEMICAL COMPANY (US) 2019-10-01 US disclosed
US-10407562-B2 Compounds with antidegradant and antifatigue efficacy and compositions including said compounds EASTMAN CHEMICAL COMPANY (US) 2019-09-10 US disclosed
US-10287418-B2 Compounds with antidegradant and antifatigue efficacy and compositions including said compounds EASTMAN CHEMICAL COMPANY (US) 2019-05-14 US disclosed
US-10260017-B2 Compounds and mixtures with antidegradant and antifatigue efficacy and compositions including said compounds EASTMAN CHEMICAL COMPANY (US) 2019-04-16 US disclosed
US-20170275237-A1 COMPOUNDS AND MIXTURES WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SAID COMPOUNDS EASTMAN CHEMICAL COMPANY (US) 2017-09-28 US disclosed
US-20170275233-A1 METHODS OF MAKING COMPOUNDS AND MIXTURES HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY EASTMAN CHEMICAL COMPANY (US) 2017-09-28 US disclosed
US-20170275234-A1 METHODS OF MAKING COMPOUNDS HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY EASTMAN CHEMICAL COMPANY (US) 2017-09-28 US disclosed
US-20170275238-A1 METHODS OF MAKING COMPOUNDS AND MIXTURES HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY EASTMAN CHEMICAL COMPANY (US) 2017-09-28 US disclosed
US-20170275233-A1 METHODS OF MAKING COMPOUNDS AND MIXTURES HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY EASTMAN CHEMICAL COMPANY (US) 2017-09-28 US disclosed
WO-2017112440-A1 COMPOUNDS WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SAID COMPOUNDS EASTMAN CHEMICAL COMPANY (US) 2017-06-29 WO disclosed
US-20170174615-A1 COMPOUNDS WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SAID COMPOUNDS EASTMAN CHEMICAL COMPANY (US) 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170275237-A1 COMPOUNDS AND MIXTURES WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SAID COMPOUNDS ACHE, CCNE2, CHRM1 ALDH1A1 1291/4885HSD17B10 1079/4885L3MBTL1 2556/4885
US-10428009-B2 Methods of making compounds and mixtures having antidegradant and antifatigue efficacy ACHE, DDO, BCHE ALDH1A1 790/4885HSD17B10 845/4885L3MBTL1 2553/4885
US-10611719-B2 Methods of making compounds and mixtures having antidegradant and antifatigue efficacy ACHE, DDO, BCHE ALDH1A1 790/4885HSD17B10 845/4885L3MBTL1 2553/4885
US-20170275234-A1 METHODS OF MAKING COMPOUNDS HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY ACHE, HNMT, PNMT ALDH1A1 603/4885HSD17B10 495/4885L3MBTL1 2029/4885
US-10260017-B2 Compounds and mixtures with antidegradant and antifatigue efficacy and compositions including said compounds ACHE, CCNE2, CHRM1 ALDH1A1 1291/4885HSD17B10 1079/4885L3MBTL1 2556/4885
US-20170275238-A1 METHODS OF MAKING COMPOUNDS AND MIXTURES HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY ACHE, BCHE, DDO ALDH1A1 730/4885HSD17B10 664/4885L3MBTL1 2559/4885
US-20170174615-A1 COMPOUNDS WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SAID COMPOUNDS ACHE, HDAC3, PON1 ALDH1A1 1067/4885HSD17B10 860/4885L3MBTL1 2609/4885
US-10407562-B2 Compounds with antidegradant and antifatigue efficacy and compositions including said compounds ACHE, HDAC3, PON1 ALDH1A1 1067/4885HSD17B10 860/4885L3MBTL1 2609/4885
US-20170275233-A1 METHODS OF MAKING COMPOUNDS AND MIXTURES HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY ACHE, DDO, BCHE ALDH1A1 790/4885HSD17B10 845/4885L3MBTL1 2553/4885
US-10287418-B2 Compounds with antidegradant and antifatigue efficacy and compositions including said compounds ACHE, HDAC3, PON1 ALDH1A1 1067/4885HSD17B10 860/4885L3MBTL1 2609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.